WO2018074758A3 - 면역질환 치료를 위한 고효능 줄기세포 선별방법 - Google Patents

면역질환 치료를 위한 고효능 줄기세포 선별방법 Download PDF

Info

Publication number
WO2018074758A3
WO2018074758A3 PCT/KR2017/010592 KR2017010592W WO2018074758A3 WO 2018074758 A3 WO2018074758 A3 WO 2018074758A3 KR 2017010592 W KR2017010592 W KR 2017010592W WO 2018074758 A3 WO2018074758 A3 WO 2018074758A3
Authority
WO
WIPO (PCT)
Prior art keywords
stem cells
highly effective
mesenchymal stem
immune disorder
immune
Prior art date
Application number
PCT/KR2017/010592
Other languages
English (en)
French (fr)
Other versions
WO2018074758A2 (ko
Inventor
유건희
이명우
김대성
Original Assignee
사회복지법인 삼성생명공익재단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사회복지법인 삼성생명공익재단 filed Critical 사회복지법인 삼성생명공익재단
Priority to CN201780077281.2A priority Critical patent/CN110088623B/zh
Priority to JP2019520694A priority patent/JP6992809B2/ja
Priority to US16/342,943 priority patent/US20190353643A1/en
Priority to EP17862140.5A priority patent/EP3527981A4/en
Publication of WO2018074758A2 publication Critical patent/WO2018074758A2/ko
Publication of WO2018074758A3 publication Critical patent/WO2018074758A3/ko

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0668—Mesenchymal stem cells from other natural sources
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G01N2333/57—IFN-gamma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90241—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)

Abstract

본 발명은, 중간엽 줄기세포에서 IFN-γ 전처리 자극후 면역억제 바이오마커의 수준을 측정하는 단계를 포함하는, 면역질환 치료를 위한 고효능 중간엽 줄기세포 선별방법, 이 방법에 의해 선별된 고효능 중간엽 줄기세포, 및 이 고효능 중간엽 줄기세포를 이용한 면역질환 치료방법에 관한 것이다. 본 발명은 이식편대숙주병, 자가면역질환을 포함하는 다양한 면역질환의 임상적 치료를 위한, 면역반응 조절능력을 가지는 기능적으로 우수한 중간엽 줄기세포를 얻을 수 있는 유용한 방법을 제공할 수 있는 바, 면역질환 치료요법으로 유용하게 이용될 수 있다.
PCT/KR2017/010592 2016-10-17 2017-09-26 면역질환 치료를 위한 고효능 줄기세포 선별방법 WO2018074758A2 (ko)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CN201780077281.2A CN110088623B (zh) 2016-10-17 2017-09-26 选择用于治疗免疫病症的高效干细胞的方法
JP2019520694A JP6992809B2 (ja) 2016-10-17 2017-09-26 免疫疾患の治療のための高効能幹細胞の選別方法
US16/342,943 US20190353643A1 (en) 2016-10-17 2017-09-26 Method For Sorting Highly Effective Stem Cells For Treating Immune Disorder
EP17862140.5A EP3527981A4 (en) 2016-10-17 2017-09-26 METHOD FOR SORTING HIGHLY EFFICIENT STEM CELLS FOR THE TREATMENT OF IMMUNE DISORDER

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2016-0134085 2016-10-17
KR1020160134085A KR101971323B1 (ko) 2016-10-17 2016-10-17 면역질환 치료를 위한 고효능 줄기세포 선별방법

Publications (2)

Publication Number Publication Date
WO2018074758A2 WO2018074758A2 (ko) 2018-04-26
WO2018074758A3 true WO2018074758A3 (ko) 2018-06-14

Family

ID=62018948

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2017/010592 WO2018074758A2 (ko) 2016-10-17 2017-09-26 면역질환 치료를 위한 고효능 줄기세포 선별방법

Country Status (6)

Country Link
US (1) US20190353643A1 (ko)
EP (1) EP3527981A4 (ko)
JP (2) JP6992809B2 (ko)
KR (1) KR101971323B1 (ko)
CN (1) CN110088623B (ko)
WO (1) WO2018074758A2 (ko)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102705670B1 (ko) * 2016-03-31 2024-09-11 샌바이오, 인크. 줄기 세포 배양 및 치료를 위한 배지, 방법, 세포 및 분비 인자
KR102074798B1 (ko) * 2018-06-15 2020-02-07 코아스템(주) 자가면역질환 치료에 대한 유효성 예측용 바이오마커, 진단키트 및 치료용 용도
KR102180111B1 (ko) * 2018-11-09 2020-11-17 코아스템(주) 단백질 키나아제 c 활성화제로 처리된 줄기세포 또는 그 배양물을 포함하는 자가면역질환 예방 또는 치료용 약학적 조성물
CN113164770B (zh) * 2018-12-14 2024-07-19 日本乐敦制药株式会社 间充质干细胞、免疫疾病治疗剂和抗炎症剂
WO2020130431A1 (ko) * 2018-12-17 2020-06-25 에스씨엠생명과학 주식회사 클로날 줄기세포를 포함하는 이식편대숙주질환 치료용 약학적 조성물
CN109674819B (zh) * 2018-12-21 2023-05-05 博雅干细胞科技有限公司 胎盘间充质干细胞制剂及其治疗硬化病的用途
KR102242285B1 (ko) * 2019-10-02 2021-04-20 코아스템(주) 중간엽줄기세포의 전신홍반루푸스 치료효과 예측용 바이오마커 조성물
WO2021162554A1 (en) * 2020-02-14 2021-08-19 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Means and methods for determining mesenchymal stromal cell properties.
WO2021169017A1 (zh) * 2020-02-25 2021-09-02 上海大学 间充质干细胞在治疗重症covid19肺炎中的用途
CN111265549B (zh) * 2020-03-02 2022-03-01 苏州大学 表面pd-l1分子过表达的间充质干细胞膜包被的仿生纳米颗粒及其制备和应用
CN111166768B (zh) * 2020-03-03 2023-03-10 南通大学 过表达ace2的间充质细胞在制备治疗新型冠状病毒药物方面的应用及其制备方法
KR102260243B1 (ko) * 2020-07-22 2021-06-03 (주)세렌라이프 효능이 증진된 줄기세포를 포함하는 항암용 조성물
CN112255410B (zh) * 2020-09-03 2023-12-05 北京臻知医学科技有限责任公司 一组用于预测2019冠状病毒病免疫检查点风暴的标志物、应用及其试剂盒
CN114395609A (zh) * 2022-02-09 2022-04-26 湖南源品细胞生物科技有限公司 一种具有高免疫调节潜力的人间充质干细胞的筛选方法
KR20240029698A (ko) 2022-08-26 2024-03-06 (주)메디노 TIMP-1, MCP-1, GROα 및 IL-6를 발현하는 고효능 줄기세포를 포함하는 신경계 질환의 예방 또는 치료용 약학적 조성물, 및 그 선별 방법
CN116139279A (zh) * 2023-01-06 2023-05-23 南京鼓楼医院 C1inh在治疗宫腔粘连中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150191699A1 (en) * 2012-07-11 2015-07-09 Imstem Biotechnology, Inc. Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
KR20170054262A (ko) * 2015-11-09 2017-05-17 사회복지법인 삼성생명공익재단 Socs가 억제된 면역억제능이 향상된 줄기세포 및 그의 이용

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2519260A2 (en) * 2009-12-31 2012-11-07 Deutsches Krebsforschungszentrum Novel modulators of trail signalling
US20140134647A1 (en) * 2012-11-01 2014-05-15 La Jolla Institute For Allergy And Immunology Novel crystal structure and ligand binding sites of trail receptor
CN102936578B (zh) * 2012-11-12 2014-09-10 山东省齐鲁干细胞工程有限公司 一种增强间充质干细胞免疫抑制功能的方法
DK2931877T3 (da) * 2012-12-14 2019-11-04 Univ Rutgers Fremgangsmåder, som modulerer stamcellers immunregulerende virkning
KR101723265B1 (ko) * 2013-08-16 2017-04-04 가톨릭대학교 산학협력단 mTOR/STAT3 신호억제제 처리된 면역조절능을 갖는 간엽줄기세포 및 이를 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물
WO2015023147A1 (ko) * 2013-08-16 2015-02-19 가톨릭대학교 산학협력단 mTOR/STAT3 신호억제제 처리된 면역조절능을 갖는 간엽 줄기세포 및 이를 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물
CN104800243B (zh) * 2014-01-28 2021-04-30 中国人民解放军军事医学科学院基础医学研究所 一种重组间充质干细胞在制备免疫抑制剂中的应用
KR101705412B1 (ko) * 2014-06-17 2017-02-09 가톨릭대학교 산학협력단 Stat3 억제제가 처리된 간엽줄기세포를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물
KR20160037113A (ko) * 2014-09-25 2016-04-05 주식회사 강스템바이오텍 인터페론-감마 또는 인터류킨-1베타를 처리한 줄기세포 또는 그 배양물을 포함하는 면역질환 또는 염증질환의 예방 또는 치료용 약학조성물
CN105331580B (zh) * 2015-12-10 2019-01-08 厦门大学 增强间充质干细胞趋化能力和趋化因子ccl5表达方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150191699A1 (en) * 2012-07-11 2015-07-09 Imstem Biotechnology, Inc. Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
KR20170054262A (ko) * 2015-11-09 2017-05-17 사회복지법인 삼성생명공익재단 Socs가 억제된 면역억제능이 향상된 줄기세포 및 그의 이용

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
LEE, MYOUNG WOO ET AL.: "Strategies to Improve the Immunosuppressive Properties of Human Mesenchymal Stem Cells", STEM CELL RESEARCH & THERAPY, vol. 6, no. 1, 7 October 2015 (2015-10-07), pages 1 - 10, XP021229541 *
POLCHERT, DAVID ET AL.: "IFN-y Activation of Mesenchymal Stem Cells for Treatment and Prevention of Graft versus Host Disease", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 38, no. 6, 20 May 2008 (2008-05-20), pages 1745 - 1755, XP055491546 *
RYAN, J. M. ET AL.: "Interferon-gamma Does not Break, but Promotes the Immuno-suppressive Capacity of Adult Human Mesenchymal Stem Cells", CLINICAL & EXPERIMENTAL IMMUNOLOGY, vol. 149, no. 2, 2007, pages 353 - 363, XP008146500 *
YOO, KEON HEE ET AL.: "Comparison of Immunomodulatory Properties of Mesenchymal Stem Cells Derived from Adult Human Tissues", CELLULAR IMMUNOLOGY, vol. 259, no. 2, 2009, pages 150 - 156, XP026614283 *

Also Published As

Publication number Publication date
CN110088623B (zh) 2022-08-09
KR101971323B1 (ko) 2019-04-23
JP2020500008A (ja) 2020-01-09
EP3527981A4 (en) 2020-06-03
CN110088623A (zh) 2019-08-02
EP3527981A2 (en) 2019-08-21
WO2018074758A2 (ko) 2018-04-26
JP6992809B2 (ja) 2022-02-15
KR20180042476A (ko) 2018-04-26
US20190353643A1 (en) 2019-11-21
JP2021184752A (ja) 2021-12-09

Similar Documents

Publication Publication Date Title
WO2018074758A3 (ko) 면역질환 치료를 위한 고효능 줄기세포 선별방법
WO2018102795A3 (en) Synthetic immune receptors and methods of use thereof
PH12019502331A1 (en) Treatment of asthma with anti-tslp antibody
MY202336A (en) Agonist antibodies that bind human cd137 and uses thereof
GEP20227419B (en) Pd-1-binding molecules and methods of use thereof
WO2016015058A3 (en) Methods of determining tissues and/or cell types giving rise to cell-free dna, and methods of identifying a disease or disorder using same
EP4219725A3 (en) Altering gene expression in modified t cells and uses thereof
CR20190550A (es) Anticuerpos que se unen específicamente a pd-1 y métodos de uso
BR112016009200A8 (pt) uso de um inibidor de btk e um inibidor imune do ponto de verificação
MX2018004600A (es) Celulas aniquiladoras naturales y células ilc3 y usos de las mismas.
MX2021009297A (es) Composiciones, dispositivos, y metodos de pruebas de sensibilidad del ibs.
MX2022000893A (es) Metodo de obtencion de mitocondrias de celulas y mitocondrias obtenidas.
NZ708033A (en) Anti-blood dendritic cell antigen 2 antibodies and uses thereof
EP4306636A3 (en) Monolayer of pbmcs or bone-marrow cells and uses thereof
MX2020009879A (es) Anticuerpos anti-il-27 y sus usos.
MX2021006980A (es) Anticuerpos anti-il-27 y usos de estos.
WO2015132790A3 (en) Anti eotaxin-2 antibodies that recognize additional ccr3-binding chemokines
TN2018000312A1 (en) Compositions and methods for treating rheumatoid arthritis
EA201590878A1 (ru) Использование ингибиторов теломеразы для лечения миелопролиферативных нарушений и миелопролиферативных неоплазм
MX2017009752A (es) Adn huesped como biomarcador de la enfermedad de crohn.
MY179946A (en) Shock absorber
WO2018224506A3 (en) AUTOIMMUN DIAGNOSIS USING T CELL POPULATIONS
MY195435A (en) Anticancer Compounds
MX2022003719A (es) Anticuerpos anti-il-27 y sus usos.
EA201992875A1 (ru) T-клетки со сниженным поверхностным фукозилированием и способы их получения и применения

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17862140

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2019520694

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2017862140

Country of ref document: EP

Effective date: 20190517